Intellia Therapeutics will discuss Q4 2025 financial results and updates on February 26, 2026, via conference call.
Quiver AI Summary
Intellia Therapeutics, Inc. announced it will host a conference call on February 26, 2026, at 8 a.m. ET to discuss its financial results for the fourth quarter and full year of 2025, along with updates on its business. Interested participants can join via a webcast or by phone, with details provided for U.S. and international callers. A replay of the call will be accessible for 90 days on the company's website. Intellia, a leading gene editing company, aims to advance medicine using CRISPR-based therapies to meet significant medical needs and is expanding its platform's capabilities.
Potential Positives
- Intellia Therapeutics is set to discuss its fourth quarter and full-year 2025 financial results, indicating transparency and engagement with shareholders.
- The company's focus on CRISPR-based therapies reinforces its position as a leader in the gene editing sector, highlighting its commitment to addressing unmet medical needs.
- The conference call will provide investors and the public with important updates on Intellia’s business, helping to build trust and investor confidence.
Potential Negatives
- Companies typically report their financial results without first announcing a conference call; the preemptive nature of this announcement may indicate a lack of confidence in their performance.
FAQ
What is the date of Intellia Therapeutics' conference call?
Intellia Therapeutics' conference call is scheduled for February 26, 2026.
How can I join the Intellia conference call?
To join, U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726.
When will the financial results be discussed?
The financial results for the fourth quarter and full-year 2025 will be discussed during the call on February 26, 2026.
Where can I access the conference call replay?
A replay of the call will be available for approximately 90 days on the Events page of Intellia's website.
What is the focus of Intellia Therapeutics?
Intellia Therapeutics focuses on revolutionizing medicine through CRISPR-based therapies for unmet medical needs.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$NTLA Insider Trading Activity
$NTLA insiders have traded $NTLA stock on the open market 13 times in the past 6 months. Of those trades, 1 have been purchases and 12 have been sales.
Here’s a breakdown of recent trading of $NTLA stock by insiders over the last 6 months:
- FRED E COHEN purchased 150,000 shares for an estimated $1,402,500
- JOHN M LEONARD (President and CEO) has made 0 purchases and 4 sales selling 122,292 shares for an estimated $1,150,869.
- DAVID LEBWOHL (EVP, Chief Medical Officer) sold 11,903 shares for an estimated $109,626
- JAMES BASTA (EVP, General Counsel) sold 10,397 shares for an estimated $95,756
- ELIANA CLARK (EVP, Chief Technical Officer) sold 9,515 shares for an estimated $87,633
- BIRGIT C SCHULTES (EVP, Chief Scientific Officer) has made 0 purchases and 2 sales selling 8,539 shares for an estimated $78,897.
- MICHAEL P DUBE (VP, Chief Accounting Officer) has made 0 purchases and 2 sales selling 4,860 shares for an estimated $60,046.
- EDWARD J III DULAC (EVP, Chief Financial Officer) sold 6,379 shares for an estimated $58,750
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$NTLA Hedge Fund Activity
We have seen 161 institutional investors add shares of $NTLA stock to their portfolio, and 161 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CONTRARIUS GROUP HOLDINGS LTD removed 5,175,456 shares (-87.9%) from their portfolio in Q4 2025, for an estimated $46,527,349
- MORGAN STANLEY removed 3,694,724 shares (-61.3%) from their portfolio in Q4 2025, for an estimated $33,215,568
- D. E. SHAW & CO., INC. added 3,102,664 shares (+139.2%) to their portfolio in Q4 2025, for an estimated $27,892,949
- GOLDMAN SACHS GROUP INC removed 2,823,058 shares (-66.0%) from their portfolio in Q4 2025, for an estimated $25,379,291
- BAKER BROS. ADVISORS LP removed 2,746,674 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $24,692,599
- ARK INVESTMENT MANAGEMENT LLC added 2,288,146 shares (+19.2%) to their portfolio in Q4 2025, for an estimated $20,570,432
- VANGUARD GROUP INC added 1,965,181 shares (+17.8%) to their portfolio in Q4 2025, for an estimated $17,666,977
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$NTLA Analyst Ratings
Wall Street analysts have issued reports on $NTLA in the last several months. We have seen 7 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- Truist Securities issued a "Buy" rating on 11/10/2025
- HC Wainwright & Co. issued a "Buy" rating on 11/10/2025
- Citizens issued a "Market Outperform" rating on 11/07/2025
- JP Morgan issued a "Underweight" rating on 11/07/2025
- Chardan Capital issued a "Buy" rating on 11/07/2025
- Barclays issued a "Overweight" rating on 11/07/2025
- JMP Securities issued a "Market Outperform" rating on 10/28/2025
To track analyst ratings and price targets for $NTLA, check out Quiver Quantitative's $NTLA forecast page.
$NTLA Price Targets
Multiple analysts have issued price targets for $NTLA recently. We have seen 13 analysts offer price targets for $NTLA in the last 6 months, with a median target of $14.0.
Here are some recent targets:
- Mitchell S. Kapoor from HC Wainwright & Co. set a target price of $25.0 on 01/28/2026
- Jonathan Miller from Evercore ISI Group set a target price of $8.0 on 11/11/2025
- Joon Lee from Truist Securities set a target price of $14.0 on 11/10/2025
- Luca Issi from RBC Capital set a target price of $9.0 on 11/07/2025
- Yanan Zhu from Wells Fargo set a target price of $12.0 on 11/07/2025
- Geulah Livshits from Chardan Capital set a target price of $26.0 on 11/07/2025
- Brian Cheng from JP Morgan set a target price of $5.0 on 11/07/2025
Full Release
CAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that the company will host a conference call on February 26, 2026, at 8 a.m. ET to discuss its fourth quarter and full-year 2025 financial results and business updates.
To join a webcast of the call, please visit this link . To join the teleconference, U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726, approximately five minutes before the call. All participants should ask to be connected to the Intellia Therapeutics conference call.
A replay of the call will be available for approximately 90 days on the Events page in the Investors & Media section of Intellia’s website, www.intelliatx.com.
About Intellia Therapeutics
Intellia Therapeutics, Inc. (Nasdaq: NTLA) is a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies. Since its inception, Intellia has focused on leveraging gene editing technology to develop novel, first-in-class medicines that address important unmet medical needs and advance the treatment paradigm for patients. Intellia’s deep scientific, technical and clinical development experience, along with its people, is helping set the standard for a new class of medicine. To harness the full potential of gene editing, Intellia continues to expand the capabilities of its CRISPR-based platform with novel editing and delivery technologies. Learn more at intelliatx.com and follow us @intelliatx .
Intellia Contact:
Jason Fredette
Vice President, Investor Relations and Corporate Communications
[email protected]
This press release was published by a CLEAR® Verified individual.
